[News] EMA guidance on radium-223 dichloride in prostate cancer

The European Medicines Agency (EMA) has issued a formal warning against using the drug Xofigo (radium-223 dichloride) in combination with Zytiga (abiraterone acetate) plus prednisone or prednisolone in patients with metastatic prostate cancer because of an increased risk of death and fractures in a review of an ongoing phase 3 trial by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC).
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research